Association of CYP2C19 genetic polymorphisms with dyslipidemia and ischemic cerebrovascular disease in the mongolian population: A case-control study.

CYP2C19

CYP2C19 poor-metaboliser status is associated with increased risk of ischemic cerebrovascular disease and heterogeneity in treatment response.

This case-control study included 300 patients with ischemic cerebrovascular disease: 150 Mongolian patients treated according to CYP2C19 genotype and 150 Han Chinese patients receiving standard care. Poor-metaboliser phenotype was associated with increased risk (OR 2.31; 95% CI 1.25-4.26; P = .008), as were hypertension (OR 1.87) and diabetes (OR 2.12). After 3 months, the genotype-guided group showed greater reductions in total and LDL cholesterol, and better neurological (NIHSS) and functional recovery (P < .001).

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The study design is fragile: the two groups differ both in ancestry and in treatment strategy, so the recovery gap cannot be attributed to genotyping. Conclusions on the benefit of guided treatment should be taken as hypotheses.

Analysis by Dr Thibaut Benquey